Investigational Testing of Bodycad Unicompartmental Knee Prosthesis (UKS)

Open-Label Investigational Testing of Bodycad Unicompartmental Knee Prosthesis (UKS) in Human Subjects With Medial Unicompartmental Knee Osteoarthritis

This study is designed to observe clinical outcomes of patient-specific knee arthroplasty in patients with osteoarthritis of the medial condyle.

Study Overview

• Status: Terminated
• Conditions: Osteoarthritis, Knee
• Intervention / Treatment: Procedure: Unicompartmental Knee Arthroplasty Surgery; Device: Bodycad Unicompartmental Knee System (BUKS)

Detailed Description

The patient-specific Bodycad Unicompartmental Knee System will be implanted on patients with knee osteoarthritis of the medial condyle. The study's hypothesis is that personalized shape and fit of patient-specific knee replacement prosthesis will provide a greater stability and a more natural knee motion in addition to a faster recovery when compared to traditional knee replacement systems. This study is designed to provide a five-years follow-up clinical data on safety and effectiveness of the device.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Geoffroy Rivet-Sabourin, PhD; Phone Number: 418-527-1388; Email: geoffroy@bodycad.com
• Study Contact Backup: Name: Marc Chaunet; Phone Number: 418-527-1388; Email: mchaunet@bodycad.com

Study Locations

• Canada
  • Quebec, Canada, G1J1Z4
    • CHU de Québec - Université Laval

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 43 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Medial unicompartmental knee osteoarthritic disease diagnosed on the basis of the American College of Rheumatology criterion with radiographic confirmation (Kellgren- Lawrence grade 3 or higher, on a scale of 0 to 4, with higher numbers indicating more severe signs of osteoarthritis); or isolated medial compartment post-traumatic arthritis supported by long film (x-ray);
2. Between the ages of at least 45 years and 70 years (inclusive) at the time of enrollment;
3. Stable health as judged by the Investigator;
4. Willingness to adhere to the protocol requirements as evidenced by the informed consent form duly read, signed and dated by the subject.

Exclusion Criteria:

1. Presence of active or latent infection in the knee;
2. Diagnosis of rheumatoid arthritis or avascular necrosis;
3. Presence of moderate patellofemoral osteoarthritic disease or patellofemoral maltracking;
4. Anterior or posterior translational, varus or valgus ligamentous knee instability and/or deformity;
5. Extension deficit > 15˚ of affected knee;
6. History of ligament surgery on the affected knee, patient that already have a prosthesis on other condyles of the affected knee and/or patient requiring a revision knee replacement surgery;
7. History of proximal tibial fracture, non-union, deformity or oblique joint line;
8. Deficient bone mass that may not provide adequate support and / or fixation;
9. Skeletal immaturity;
10. Obesity: BMI above 35
11. Risk of exposing the prosthesis to overload by the practice of contact or high impact sports such as: baseball, hockey, basketball, football, soccer, karate, skiing etc;
12. Known sensitivity to CoCrMo, Titanium, and polyethylene components of the UKS Prosthesis used in the manufacturing of the prosthesis;
13. Pre-existing medical conditions such as history of cancer other than skin cancer, poorly controlled diabetes, systemic infections, immunocompromised, fibromyalgia or other general body pain conditions, which, in the opinion of the Investigator, interfere with the conduct of the study;
14. Neuromuscular condition that could lead to an unacceptable risk of instability of the prosthesis or other postoperative complications;
15. Subjects, in the opinion of the Investigator, who are unlikely to comply with the protocol (e.g. active alcoholism, drug dependency or psychotic state, unable or unwilling to adhere to study visit schedule);
16. Pregnant or nursing female subjects; or female subjects planning on becoming pregnant within the next 60 months from enrollment;
17. Subjects under guardianship, hospitalized in a public or private institution, for a reason other than research, or subject deprived of freedom;
18. Participation in an active stage of any drug, intervention or treatment trial within 30 days of enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Knee Arthroplasty using BUKS; Unicompartmental Knee Arthroplasty Surgery	Procedure: Unicompartmental Knee Arthroplasty Surgery; Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS); Device: Bodycad Unicompartmental Knee System (BUKS); Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Knee Society Score (KSS) Objective	Assessment of improvement of clinical outcomes following BUKS implantation using the KSS questionnaire, to evaluate the clinical performance of the articulation	Baseline, post-operative months 3, 6, 12, 24, 36, 48 and 60
Change from baseline in Knee Osteoarthritis Outcome Score (KOOS)	Assessment of improvement of activity levels following BUKS implantation surgery using the KOOS questionnaire	Baseline, post-operative months 3, 6, 12, 24, 36, 48 and 60

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in mechanical axis measurement.	Determine by radiographic analysis Varus or Valgus, expected value are +/- 3 degrees	Baseline and post operative week 1
Change from baseline of implant position fixation	The anteroposterior and medial lateral slop will be evaluated according to initial planed position. The measured angles will be compared with initial planning. The expected values are +/- 1.5 degree.	Post operative week 6, months 6, 12, 24, 36, 48 and 60
Change from baseline on bone loss and cementation	Those measurements will be done on x-ray of the patient joint following Knee Society Radiological evaluation form.The tibial component acceptable score for this device will be 2.5 mm. The femoral component acceptable score for this device will be 6 mm.	Post operative week 6, months 6, 12, 24, 36, 48 and 60

Collaborators and Investigators

• Sponsor: Laboratoires Bodycad Inc.
• Investigators: Principal Investigator: Etienne Belzile, MD, CHU de Quebec - Hopital de l'Enfant-Jésus; Study Chair: Brian Hamlin, MD, Renaissance Orthopedics; Study Director: Geoffroy Rivet-Sabourin, PhD, Laboratoires Bodycad Inc.

Study record dates

Study Major Dates

• Study Start (Actual): January 24, 2018
• Primary Completion (Actual): August 20, 2020
• Study Completion (Actual): March 7, 2023

Study Registration Dates

• First Submitted: January 22, 2018
• First Submitted That Met QC Criteria: February 7, 2018
• First Posted (Actual): February 14, 2018

Study Record Updates

• Last Update Posted (Actual): August 25, 2023
• Last Update Submitted That Met QC Criteria: August 23, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Osteoarthritis, Knee
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: PRO-PB001-42

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No